OncoDEEP test aims at guiding oncologists in their treatment decision making. Thanks to an intelligent combination of comprehensive tumor molecular characterization integrating sophisticated tumor interrogation technologies (NGS, IHC, pyrosequencing,...) together with an extensive clinical literature assessment, we provide you with the most relevant evidence on biomarkers and their drugs correlation.

Our multiplex platform helps guide therapy decisions when there is little to no medical treatment consensus or guideline and offers you to:

- **Navigate** among therapies with potential clinical benefit
- **Identify** therapies that may not have been considered previously
- **Detect** drugs with potential lack of clinical benefit (thus avoiding unnecessary toxicities and costs)
- **Match** patients to clinical trial opportunities

**MATERIAL**

- 1 block or 20 slides (5μm on super Frost+)

**TUMOR MOLECULAR PROFILING**

- **Next-generation sequencing**
  - More than 70 genes
  - Depth of coverage at a median of 1000x

- **Cancer type specific package**
  - IHCs for targeted therapies
  - IHCs for chemotherapies
  - IHCs for immunotherapies
  - Other (translocation analysis, methylation)
  - **NEW!** Immunogram (MSI + TMB)

**INTEGRATED THERANOSTIC REPORT**

- Molecular characterization of the tumor
- Treatment options for targeted therapies, chemotherapies and immunotherapies
- Clinical trials availability

OncoDEEP is IVD CE-marked and processed in an ISO 15189 accredited laboratory.
WHY IS ONCODEEP UNIQUE?

OncoDEEP is the most cost-effective test on the market for tumor molecular characterization focusing on cancer-specific diagnostic biomarkers. It is based on an integrative analysis of cancer specific-related signaling pathways through a multidimensional approach combining DNA/RNA and protein analyses and provides the most actionable information that you need to make important treatment decisions.

Data generated from both the next-generation sequencing and molecular pathology analyses are integrated and interpreted in a biological review. Our reports are sent to oncologists worldwide via our interactive web platform OncoSHARE, an innovative and proprietary application specifically created to centralize data, facilitate their access and guarantee their confidentiality.

HOW LONG DOES IT TAKE TO GET THE RESULTS?

After OncoDNA has received and QC checked the solid biopsy and all the required clinical information, we are committed to sending the report within 7 working days.

WHO IS THIS TEST FOR?

OncoDEEP is designed to be used when therapeutic ambiguities exist in adult patients with solid tumors:

- Multiple treatment options for standard therapies
- Standard options cannot be considered due to comorbidities
- Standards of care have been exhausted
- Highly aggressive cancers
- Rare or less frequent tumors